` ETNB (89Bio Inc) vs S&P 500 Comparison - Alpha Spread

ETNB
vs
S&P 500

Over the past 12 months, ETNB has significantly outperformed S&P 500, delivering a return of +87% compared to the S&P 500's +14% growth.

Stocks Performance
ETNB vs S&P 500

Loading
ETNB
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ETNB vs S&P 500

Loading
ETNB
S&P 500
Difference
www.alphaspread.com

Performance By Year
ETNB vs S&P 500

Loading
ETNB
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
89Bio Inc vs Peers

S&P 500
ETNB
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

89Bio Inc
Glance View

Market Cap
2.2B USD
Industry
Biotechnology

89bio, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 41 full-time employees. The company went IPO on 2019-11-11. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The firm's lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. The firm's subsidiaries include 89Bio Ltd, 89bio Management, Inc. and UAB 89bio Lithuania.

ETNB Intrinsic Value
Not Available
Back to Top